Total doses of 2.4 g/m2 to 3.5 g/m2 administered intravenously over three days have resulted in severe mucositis and myelotoxicity. Metabolic acidosis and cases of serious hepatic toxicity have been reported in patients receiving higher than recommended intravenous doses of etoposide.
Similar toxicities can be expected with oral formulation.
A specific antidote is not available. Treatment should therefore be symptomatic and supportive, and patients should be closely monitored.
Etoposide and its metabolites are not dialysable.